Raloxifene
RALOXIFEN · Evista · (6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-yl)ethoxy)phenyl)Methanone · RALOXAFINE · RALOXIFENE · RALOXIFENE-D7 · Raloxifene CRS · LY156758 free base
식별자 및 물리적 특성
| CAS No. | 82640-04-8 |
|---|---|
| 분자식 | C28H27NO4S |
| 평균 분자량 | 473.6 g/mol |
| 단동위원소 질량 | 473.16607934 g/mol |
| SMILES | O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12 |
| InChIKey | GZUITABIAKMVPG-UHFFFAOYSA-N |
| PubChem CID | 5035 |
| ChEMBL | CHEMBL81 |
| ChEBI | CHEBI:8772 |
| EC No. | 686-786-1 |
| DTXSID | DTXSID3023550 |
화학 및 물리적 성질
| XLogP | 6.1 |
|---|---|
| 극성 표면적 | 98.2 |
| 수소 결합 공여자 수 | 2 |
| 수소 결합 수용자 수 | 6 |
| 회전 가능 결합 수 | 7 |
| 무거운 원자 수 | 34 |
| 형식 전하 | 0 |
| 복잡도 | 655 |
| 물질 분류 | Pharmaceutical |
| 의약품 | Pharmaceuticals -> Listed in ZINC15 |
| LogP(분배 계수) | 5.24.48 |
| Color/Form | Crystals from acetone |
| 용해도 | Insoluble5.12e-04 g/LDMSO: 28mg/mL, 용해성 |
| Human Drugs | EMA approved medicines: Human medicinePharmaceuticals |
| Endocrine Disruptors | Potential endocrine disrupting compound |
| 녹는점 | 268-272143-147 °CCrystals from methanol/watermp: 258 °CUV max (ethanol): 286 nm (epsilon 32800). Freely soluble in dimethylsulfoxidesparingly soluble in methanolslightly soluble in alcoholvery slightly soluble in water, isopropyl alcohol, octanol. Practically insoluble in ether, ethyl acetate /Raloxifene hydrochloride/143 - 147 °C250-253°C |
| Physical Description | Solid |
| Stability/Shelf Life | Stable under recommended storage conditions. /Raloxifene hydrochloride/ |
| Collision Cross Section | 213.4 Ų [M-H]- [CCS Type: DTBuffer gas: N2Ionization: ESI-Dataset: TOXCASTSource Identifier: DTXSID1034181]212.74 Ų [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards] |
| 끓는 점 | 728.2±60.0 °C(Predicted) |
| 밀도 | 1.289±0.06 g/cm3(Predicted) |
| 저장 조건 | Desiccate at +4°C |
| pKa(산도 계수) | 8.83±0.15(Predicted) |
| 물리적 상태 | 고체 |
| 색상 | 연노랑 |
| 용해도 | 560μg/L at 25℃ |
| InChI | InChI=1S/C28H27NO4S/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29/h4-13,18,30-31H,1-3,14-17H2 |
| InChIKey | GZUITABIAKMVPG-UHFFFAOYSA-N |
| SMILES | C(C1=C(C2=CC=C(O)C=C2)SC2=CC(O)=CC=C21)(C1=CC=C(OCCN2CCCCC2)C=C1)=O |
| LogP(분배 계수) | 6.09 |
화학적 성질
Light-Yellow Solid
안전 및 규제
| GHS 분류 | DangerH302 (33.3%): Harmful if swallowed [Warning Acute toxicity, oral]P203, P261, P262, P264, P264+P265, P270, P271, P273, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P316, P317, P318, P319, P321, P330, P332+P317, P337+P317, P361+P364, P362+P364, P391, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 3 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| 규제 정보 | Status: Active Update: 28-04-2022 https://echa.europa.eu/registration-dossier/-/registered-dossier/33491 |
| FDA 요건 | The Approved Drug Products with Therapeutic Equivalence Evaluations identifies currently marketed prescription drug products, including raloxifene hydrochloride, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Raloxifene hydrochloride/ |
| Toxic Combustion Products | Special hazards arising from the substance or mixture: Carbon oxides, Nitrogen oxides (NOx), Sulfur oxides, Hydrogen chloride gas. /Raloxifene hydrochloride/ |
| Hazard Classes and Categories | Acute Tox. 4 (33.3%) |
| Shipment Methods and Regulations | /PRECAUTIONS FOR ANTINEOPLASTIC AGENTS:/ Methods for transporting hazardous drugs to the health-care setting should be consistent with environmental protection and national or local regulations for transporting hazardous substances. When hazardous drugs are being transported to the home-care setting, appropriate containers (eg, lined cardboard boxes) and procedures should be used to prevent breakage and contain leakage. ... The drugs must be securely capped or sealed and properly packaged and protected during transport to reduce further the chance of breakage and spillage in a public area such as a corridor or elevator. /Antineoplastic agents/ |
| 소화 절차 | Suitable extinguishing media: Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. /Raloxifene hydrochloride/Advice for firefighters: Wear self-contained breathing apparatus for fire fighting if necessary. /Raloxifene hydrochloride/ |
| 보관 조건 | Store at controlled room temperature, 20 deg to 25 °C (68 deg to 77 °F) [see USP]. The USP defines controlled room temperature as a temperature maintained thermostatically that encompasses the usual and customary working environment of 20 deg to 25 det C (68 deg to 77 °F) |
용도
용도
Raloxifene is a nonsteroidal, selective estrogen receptor modulator (SERM). Antiosteoporotic.
일반 설명
Raloxifene, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone (Evista), is a benzothiophene derivativethat differs slightly from the triphenylethyleneSERMs. A key structural difference is the carbonyl “hinge”that connects the modified phenolic side chain to the benzothiophenering system. This hinge is the key structural elementthat leads to the differing actions at the ERs.Raloxifene, unlike tamoxifen and toremifene, has antagonistproperties on the endometrium and breast tissue and agonistproperties on bone and the cardiovascular system. The lackof agonist action on endometrial tissue has been suggestedas a reason for the lack of endometrial cancer associatedwith raloxifene use. Raloxifene is approved for the preventionand treatment of osteoporosis in postmenopausalwomen. It has also been investigated for preventing breastcancer in comparison with tamoxifen. Recent studies indicatesthat it has similar effectiveness to tamoxifen, but has apreferable side effect profile.